Acinetobacter信息详情
n.不动杆菌属
OBJECTIVE To investigate the antibiotic resistant phenotyping of Acinetobacter spp on NC21 panel.───目的研究不动杆菌属在NC21板上耐药表型及比率。
However, there is a growing threat from a new family of bacterial infection including Acinetobacter, which affects around 1,000 patients each year.───然而，包括不动杆菌在内的新细菌感染家族的威胁日益严重，每年影响到约1000名患者。
This review emphasizes on the mechanisms of resistance to selected antibiotics in Acinetobacter baumannii.───这篇综述着重介绍了鲍曼不动杆菌对所选抗生素的耐药机制。
Objective To understand clinical distribution and drug-resistance features of Acinetobacter baumannii.───目的了解鲍曼不动杆菌的临床分布情况及耐药特点。
Now (MRSA) and a new emerging emerging Gram-negative bacteria bacterium, which is called multidrug-resistant Acinetobacter baumann i.───另外一种是新发现的革兰氏阴性细菌，叫多重耐药性鲍曼不动杆菌。
If treatment was on the basis of drug sensitivity results, it was of significance to the clinical treatment of Acinetobacter baumannii.───根据药敏结果用药，对指导临床治疗鲍曼不动杆菌具有重要意义。
OBJECTIVE To investigate the causes and regularities of Acinetobacter infection of the non healing wounds of fracture patients.───目的探讨骨折患者伤口不愈合不动杆菌感染的原因、规律，以利防范。
Objective To investigated the clinical infections distribution of Acinetobacter baumanii and its drug resistance.───目的了解临床鲍曼不动杆菌感染分布及耐药情况。
Objective To analyze the plasmid and resistant spectra and the location of the resistance gene of Acinetobacter baumannii .───目的分析鲍氏不动杆菌的质粒谱和耐药谱，找出它们的耐药基因位点。
Methods Isolates were identified as acinetobacter calcoaceticus by using antibiotic susceptibility test, plasmid profiles, restriction enzyme fingerprinting assay and plasmid elimination method.
), Klebsiella ( 10 % ), Acinetobacter ( 8 % ), and Salmonella typhi ( 8 % ).
Aeromonas genus 13.13 %, Acinetobacter spp. 7.02 %, Pseudomonas spp.
Acinetobacter baumanii and Staphylococcus aurous could be found from their air of surroundings, hands of accompanying persons, nasal vestibule of healthy care workers et.
Objective To develop a novel multiplex polymerase chain reaction ( PCR ) to detect multidrug - resistant Acinetobacter baumannii.
coli ( 27 % ), Pseudomonas aeruginosa ( 14 % ), Klebsiella ( 10 % ), Acinetobacter ( 8 % ), and Salmonella typhi ( ...
RESULTS: Cefepime has high in vitro antimicrobial activity against enteric bacilli, P. aeruginosa, acinetobacter and oxacillin -susceptible staphylococci.